US health regulators have approved to restart the use of Johnson & Johnson Covid vaccine. It was paused due to worries over blood clotting.
"We have concluded that the known and potential benefits of the Janssen Covid-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older," said Janet Woodcock, head of Food and Drug Administration in a joint statement with the Centers for Disease Control and Prevention (CDC).
According to data presented recently, out of 3.9 million women who got the Johnson & Johnson jabs, 15 developed serious blood clots and three died. The majority of the confirmed cases, 13 of the 15, were aged under 50 years old.
CDC has listed it as "exceptionally rare events" of clotting, adding that regulators will continue to monitor the rollout of the vaccines.
"We have concluded that the known and potential benefits of the Janssen Covid-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older," said Janet Woodcock, head of Food and Drug Administration in a joint statement with the Centers for Disease Control and Prevention (CDC).
According to data presented recently, out of 3.9 million women who got the Johnson & Johnson jabs, 15 developed serious blood clots and three died. The majority of the confirmed cases, 13 of the 15, were aged under 50 years old.
CDC has listed it as "exceptionally rare events" of clotting, adding that regulators will continue to monitor the rollout of the vaccines.
